Principal Financial Group
GTHX

Principal Financial Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Principal Financial Group’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,687
Closed -$213K – 2633
2021
Q2 		$213K Buy
9,687
+1,239
+15% +$27.5K ﹤0.01% 2458
2021
Q1 		$203K Buy
+8,448
New +$196K ﹤0.01% 2382
2018
Q4 		– Sell
-8,307
Closed -$435K – 2322
2018
Q3 		$435K Buy
+8,307
New +$453K ﹤0.01% 1990

Other funds holding GTHX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Principal Financial Group's GTHX Position: Q3 2021 in Review

Principal Financial Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2021, closing a stake of 9,687 shares — an estimated $213K sold.

Principal Financial Group first reported a position in GTHX in Q3 2018 and held it in 3 quarters. The position peaked at $435K in Q3 2018. 115 funds tracked by Wall St. Rank hold GTHX as of Q3 2021.

  • Principal Financial Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Principal Financial Group sold 9,687 G1 Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $213K.
  • Principal Financial Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Principal Financial Group's G1 Therapeutics, Inc. Common Stock position peaked at $435K in Q3 2018.
  • 115 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Principal Financial Group's 13F filing for Q3 2021, filed 9 Nov 2021.